On November 12, 2020 Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, reported its third quarter 2020 results today (Press release, Ultimovacs, NOV 12, 2020, View Source [SID1234570679]). A presentation by the Company’s management team will take place today on a webcast at 09:00 CEST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation can be followed as a live webcast, accessible directly through this link or through the link displayed under Reports and Presentations in the investor section of Ultimovacs’ corporate website www.ultimovacs.com.

Highlights for the third quarter of 2020:

In the INITIUM trial, a total of twelve patients have been enrolled as per reporting date (compared to three patients reported in the previous quarterly report). INITIUM is a randomized, multi-center Phase II trial evaluating UV1 as a treatment for first-line patients with metastatic malignant melanoma.
In the NIPU trial, a total of six patients have been enrolled as per reporting date (compared to four patients reported in the previous quarterly report). NIPU is a randomized, multi-center Phase II trial in which UV1 is investigated as a second-line treatment in mesothelioma.
The Covid-19 situation has so far had fairly limited impact regarding site openings and patient inclusion in the Phase II clinical trials. The longer-term effect of the pandemic on the biotech industry and the general ability to conduct clinical trials is still uncertain.
In the fully enrolled US-based Phase I trial in malignant melanoma, positive topline results from the first cohort of 20 patients were announced in September 2020. The results confirm achievement of the primary endpoints of safety and tolerability and indicate initial signs of clinical response; the 12-month Overall Survival (OS) rate was 85% and median Progression Free Survival (mPFS) was not reached after 12 months.
Five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer was reported in October 2020. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit. At the five-year landmark, the OS rate was 33% and mPFS was 10.7 months. (Post-period event)
In May 2020, Ultimovacs announced a collaboration with a non-specified big pharma company and a leading European oncology clinical trial group to evaluate UV1 in a third Phase II clinical trial. As communicated in September 2020, finalization of the agreement and announcement of the collaboration is expected during the fourth quarter of 2020.
The regulatory approval is now in place to start the Phase I TENDU trial. This trial will investigate a prostate cancer specific vaccine based on the TET technology. The first patient is expected to be enrolled in the first quarter of 2021.
Total operating expenses amounted to MNOK 31.1 in Q3-20 and MNOK 98.6 YTD. Cash flow from operations was MNOK -29.6 in Q3-20. Total cash and cash equivalents were reduced by MNOK 29.2 during Q3-20, amounting to MNOK 453.5 as per 30 September 2020.
The full report and presentation are also available under Reports and Presentations in the investor section of Ultimovacs’ corporate website www.ultimovacs.com.

On November 11, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, reported that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 (Press release, Cue Biopharma, NOV 11, 2020, View Source [SID1234608290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cue Biopharma will provide an overview highlighting the Immuno-STAT (Selective Targeting and Alteration of T cells) platform, its expanding pipeline and anticipated milestones. The presentations will also include an update on the Company’s ongoing Phase 1 monotherapy dose escalation trial of CUE-101 including details pertaining to patients from cohorts 4, 5, and 6 being treated for HPV16-driven recurrent/metastatic head and neck cancer.

Additional conference details can be found below:

Stifel Virtual Healthcare Conference 2020
Date and Time: November 18, 2020 at 9:20 a.m. EST
Webcast Link: View Source
A live and archived webcast of the presentation will be available in the Investors section of the Company’s website at www.cuebiopharma.com. .

Jefferies Virtual London Healthcare Conference
Date and Time: November 19, 2020 at 9:05 a.m. EST
Webcast link: View Source
A live and archived webcast of the presentation will be available in the Investors section of the Company’s website at www.cuebiopharma.com. .

On November 11, 2020 Bristol Myers Squibb (NYSE: BMY) reported that the company will take part in a fireside chat at Wolfe Research’s 2nd Annual Virtual Healthcare Conference, which will be webcast on Wednesday, November 18, 2020 (Press release, Bristol-Myers Squibb, NOV 11, 2020, View Source [SID1234573351]). Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will answer questions about the company at 9:15 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.

On November 11, 2020 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, reported that its Chief Executive Officer, Jesse Shefferman, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 1:45pm ET (Press release, Protara Therapeutics, NOV 11, 2020, View Source [SID1234573136]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived on the Company’s website for 90 days following the presentation.

On November 11, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) and Cherry Biolabs GmbH, a spin-off from the University Hospital Würzburg, reported that they entered into a licensing agreement granting MorphoSys the rights to apply Cherry Biolabs’ innovative, multispecific Hemibody technology to six exclusive targets (Press release, MorphoSys, NOV 11, 2020, View Source [SID1234571034]). This Hemibody technology, in combination with MorphoSys’ antibody know-how and technologies, offers the potential to generate novel T-cell engaging medicines with higher precision and better safety profiles for the treatment of cancer patients. Financial details were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As part of its internal research efforts, MorphoSys is continuously looking to add new cutting-edge technologies with the aim of generating differentiated, more efficacious and safer antibody-based therapeutics for its proprietary pipeline, and the licensing agreement with Cherry Biolabs is an important step towards developing new treatments for cancer patients with unmet medical needs", commented Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "The combination of MorphoSys’ proven track record in antibody discovery and development and Cherry Biolabs’ Hemibody technology has the potential to significantly broaden therapeutic approaches and improve patients’ lives."

"Hemibodies are antibody fragments that gain T-cell engaging capabilities after binding to an antigen combination unique to tumor cells. Through its combinatorial pro-drug design, the Hemibody platform technology bears the potential to significantly increase the specificity of cancer treatments and reduce toxicity," added Cherry Biolabs founder and Chief Executive Officer Prof. Gernot Stuhler. "With MorphoSys, we have found a very strong and competent licensee embracing this new modality-we are confident that MorphoSys will bring this innovative concept into the clinic to make a difference for patients".

Harnessing the body’s own immune system in the fight against a fast growing cancer is an extremely promising therapeutic approach. T-cell engaging bispecific antibodies are meant to recruit and activate T-cells and direct cytotoxic activity to the tumor cells. "Today’s T-cell engaging bispecific antibody approaches have their challenges, particularly when applied to solid cancers. The often limited specificity of the tumor target typically hampers tolerability and thereby clinical efficacy. We believe that through dual targeting and highly specific activation of the cytotoxic T-cells at the tumor site-which is what the Hemibody technology promises to provide-we will be able to take the precision and specificity of the tumor targeting concept to the next level and enable a substantially enlarged therapeutic window", said Dr. Martin Steegmaier, Head of Research at MorphoSys.

Cherry Biolabs’ Hemibody technology was first discovered by Prof. Gernot Stuhler and Dr. Thomas Bumm at the Julius-Maximilians-University of Würzburg, Germany and is funded by the "GO-Bio Gründungsoffensive Biotechnologie" from the German Federal Ministry of Education and Research. Cherry was represented by EMBL Ventures in the negotiations to close this first, important licensing for the company.

MorphoSys intends to apply the Hemibody technology in the context of its CyCAT(R) (Cytotoxic Cell Activation at Tumor) Dual Targeting Concept to discover and advance novel Hemibody-based treatment options for patients with hematological and solid cancers, in line with its mission to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.